• In March 2026, ImmunityBio received an FDA warning letter over allegedly misleading promotional claims for its bladder cancer drug Anktiva, triggering multiple securities class action lawsuits that allege misrepresentation and securities fraud.
• At the same time, the company has reported very large year-over-year product revenue growth and accelerating global adoption of Anktiva, creating a tension between operational momentum and heightened legal and regulatory risk.
• We’ll now examine how the FDA warning letter and ensuing class action lawsuits affect ImmunityBio’s previously optimistic investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 39 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

ImmunityBio Investment Narrative Recap

To own ImmunityBio today, you need to believe Anktiva can support a broader immunotherapy platform while evolving beyond a single product story. The key short term catalyst is continued commercial uptake and potential label expansion in bladder cancer, now complicated by the FDA warning letter and securities class actions that introduce meaningful regulatory and legal risk to management’s optimistic narrative.

Against this backdrop, ImmunityBio’s preliminary first quarter 2026 update, highlighting about US$44.2 million in net product revenue and 168% year over year growth driven by Anktiva, is especially relevant. It underscores how quickly the commercial base is building at the same time regulators are scrutinizing how the drug is promoted, sharpening the trade off between rapid adoption and compliance risk.

Yet behind the headline growth, investors also need to understand the heightened regulatory scrutiny and securities litigation that could...

ImmunityBio's narrative projects $1.2 billion revenue and $435.5 million earnings by 2029. This requires 118.9% yearly revenue growth and an earnings increase of about $786.9 million from -$351.4 million today.

Uncover how ImmunityBio's forecasts yield a $13.50 fair value, a 78% upside to its current price.

Exploring Other Perspectives

Before the FDA letter, the most pessimistic analysts were still modeling roughly US$895.3 million of revenue and US$418.7 million of earnings by 2029, but they also flagged that any regulatory clampdown on single arm data for lung cancer could sharply reset those expectations, showing how far views can diverge and why it is worth comparing several possible paths for ImmunityBio.

Explore 9 other fair value estimates on ImmunityBio - why the stock might be worth less than half the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your ImmunityBio research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free ImmunityBio research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ImmunityBio's overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.